161 related articles for article (PubMed ID: 7714116)
1. Relationship of proinsulin and insulin with noninsulin-dependent diabetes mellitus and coronary heart disease in Japanese-American men: impact of obesity--clinical research center study.
Kahn SE; Leonetti DL; Prigeon RL; Boyko EJ; Bergstrom RW; Fujimoto WY
J Clin Endocrinol Metab; 1995 Apr; 80(4):1399-406. PubMed ID: 7714116
[TBL] [Abstract][Full Text] [Related]
2. Disproportionately elevated proinsulin in Pima Indians with noninsulin-dependent diabetes mellitus.
Saad MF; Kahn SE; Nelson RG; Pettitt DJ; Knowler WC; Schwartz MW; Kowalyk S; Bennett PH; Porte D
J Clin Endocrinol Metab; 1990 May; 70(5):1247-53. PubMed ID: 2186054
[TBL] [Abstract][Full Text] [Related]
3. Proinsulin as a marker for the development of NIDDM in Japanese-American men.
Kahn SE; Leonetti DL; Prigeon RL; Boyko EJ; Bergstrom RW; Fujimoto WY
Diabetes; 1995 Feb; 44(2):173-9. PubMed ID: 7859937
[TBL] [Abstract][Full Text] [Related]
4. Disproportionately elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus.
Røder ME; Porte D; Schwartz RS; Kahn SE
J Clin Endocrinol Metab; 1998 Feb; 83(2):604-8. PubMed ID: 9467581
[TBL] [Abstract][Full Text] [Related]
5. Proinsulin levels predict the development of non-insulin-dependent diabetes mellitus (NIDDM) in Japanese-American men.
Kahn SE; Leonetti DL; Prigeon RL; Boyko EJ; Bergstom RW; Fujimoto WY
Diabet Med; 1996 Sep; 13(9 Suppl 6):S63-6. PubMed ID: 8894485
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activator inhibitor (PAI-1) activity is elevated in Asian and Caucasian subjects with non-insulin-dependent (type 2) diabetes but not in those with impaired glucose tolerance (IGT) or non-diabetic Asians.
Nagi DK; Mohamed Ali V; Jain SK; Walji S; Yudkin JS
Diabet Med; 1996 Jan; 13(1):59-64. PubMed ID: 8741814
[TBL] [Abstract][Full Text] [Related]
7. Plasma insulin, C-peptide, and proinsulin concentrations in obese and nonobese individuals with varying degrees of glucose tolerance.
Reaven GM; Chen YD; Hollenbeck CB; Sheu WH; Ostrega D; Polonsky KS
J Clin Endocrinol Metab; 1993 Jan; 76(1):44-8. PubMed ID: 8421101
[TBL] [Abstract][Full Text] [Related]
8. Effect of sulfonylurea withdrawal on proinsulin levels, B cell function, and glucose disposal in subjects with noninsulin-dependent diabetes mellitus.
Prigeon RL; Jacobson RK; Porte D; Kahn SE
J Clin Endocrinol Metab; 1996 Sep; 81(9):3295-8. PubMed ID: 8784086
[TBL] [Abstract][Full Text] [Related]
9. Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM.
Kahn SE; Halban PA
Diabetes; 1997 Nov; 46(11):1725-32. PubMed ID: 9356018
[TBL] [Abstract][Full Text] [Related]
10. Total immunoreactive proinsulin, immunoreactive insulin and specific insulin in relation to conversion to NIDDM: the Mexico City Diabetes Study.
Haffner SM; Gonzalez C; Mykkänen L; Stern M
Diabetologia; 1997 Jul; 40(7):830-7. PubMed ID: 9243105
[TBL] [Abstract][Full Text] [Related]
11. Proinsulin immunoreactivity in identical twins discordant for noninsulin-dependent diabetes mellitus.
Røder ME; Vaag A; Hartling SG; Dinesen B; Lanng S; Beck-Nielsen H; Binder C
J Clin Endocrinol Metab; 1995 Aug; 80(8):2359-63. PubMed ID: 7629230
[TBL] [Abstract][Full Text] [Related]
12. [The clinical significance of true insulin and proinsulin levels in subjects with different glucose tolerance].
Yang J; Li M; Wu C
Zhonghua Nei Ke Za Zhi; 2000 Dec; 39(12):811-3. PubMed ID: 11798541
[TBL] [Abstract][Full Text] [Related]
13. Incidence of non-insulin-dependent diabetes mellitus and its risk factors in Japanese-Americans living in Hawaii and Los Angeles.
Hara H; Egusa G; Yamakido M
Diabet Med; 1996 Sep; 13(9 Suppl 6):S133-42. PubMed ID: 8894497
[TBL] [Abstract][Full Text] [Related]
14. Proinsulin and specific insulin concentration in high- and low-risk populations for NIDDM.
Haffner SM; Bowsher RR; Mykkänen L; Hazuda HP; Mitchell BD; Valdez RA; Gingerich R; Monterossa A; Stern MP
Diabetes; 1994 Dec; 43(12):1490-3. PubMed ID: 7958504
[TBL] [Abstract][Full Text] [Related]
15. Are insulin and proinsulin independent risk markers for premature coronary artery disease ?
Katz RJ; Ratner RE; Cohen RM; Eisenhower E; Verme D
Diabetes; 1996 Jun; 45(6):736-41. PubMed ID: 8635646
[TBL] [Abstract][Full Text] [Related]
16. Age-related alteration of pancreatic beta-cell function. Increased proinsulin and proinsulin-to-insulin molar ratio in elderly, but not in obese, subjects without glucose intolerance.
Shimizu M; Kawazu S; Tomono S; Ohno T; Utsugi T; Kato N; Ishi C; Ito Y; Murata K
Diabetes Care; 1996 Jan; 19(1):8-11. PubMed ID: 8720525
[TBL] [Abstract][Full Text] [Related]
17. Hyperproinsulinemia of type II diabetes is not present before the development of hyperglycemia.
Birkeland KI; Torjesen PA; Eriksson J; Vaaler S; Groop L
Diabetes Care; 1994 Nov; 17(11):1307-10. PubMed ID: 7821172
[TBL] [Abstract][Full Text] [Related]
18. Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin:insulin ratio in type 2 diabetes.
Smith SA; Porter LE; Biswas N; Freed MI
J Clin Endocrinol Metab; 2004 Dec; 89(12):6048-53. PubMed ID: 15579757
[TBL] [Abstract][Full Text] [Related]
19. Coronary heart disease and NIDDM in Japanese-Americans.
Fujimoto WY; Bergstrom RW; Boyko EJ; Leonetti DL; Newell-Morris LL; Wahl PW
Diabetes; 1996 Jul; 45 Suppl 3():S17-8. PubMed ID: 8674882
[TBL] [Abstract][Full Text] [Related]
20. Reduced pancreatic B cell compensation to the insulin resistance of aging: impact on proinsulin and insulin levels.
Røder ME; Schwartz RS; Prigeon RL; Kahn SE
J Clin Endocrinol Metab; 2000 Jun; 85(6):2275-80. PubMed ID: 10852463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
